Covidien (NYSE:COV) hit a new 52-week high Friday as it is currently trading at $60.89, above its previous 52-week high of $60.81 with 1.2 million shares traded as of 1:15 p.m. ET. Average volume has been 2.3 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Covidien (NYSE: COV) hit a new 52-week high Friday as it is currently trading at $60.89, above its previous 52-week high of $60.81 with 1.2 million shares traded as of 1:15 p.m. ET. Average volume has been 2.3 million shares over the past 30 days. Covidien has a market cap of $28.42 billion and is part of the health care sector and health services industry. Shares are up 4.4% year to date as of the close of trading on Thursday. Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company has a P/E ratio of 15.3, below the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Covidien Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.